The United States extends the scope for the use of vaccines against cancer and HPV-related diseases

The US Food and Drug Administration has just approved an additional application for garda 9 (Vaccine 9-Papentomavirus Human Papillomavirus-HPV, Recombinant), expanding the use of this vaccine for women and men from 27 to 45 years old.

This approval is an important opportunity to help prevent cancer and diseases caused by 9 types of HPV in a wider range. This vaccine can prevent more than 90% of HPV-related cancers.

HPV virus is associated with several other types of cancer affecting men and women.

According to CDC (US Centers for Disease Control and Prevention), about 14 million Americans are infected with HPV each year; About 12,000 women are diagnosed and about 4,000 women die from cervical cancer due to some HPV viruses. In addition, HPV is associated with a number of other cancers that affect men and women.

Gardasil, a vaccine approved by the FDA in 2006 to prevent certain types of cancer and diseases caused by four types of HPV. In 2014, the FDA approved the garda 9, including four garda-like HPV types and added five more HPV types and gardasil 9 approved for use in men and women from 9 to 26 years old.

Gardasil's efficacy is related to gardas 9 because vaccines are produced similarly and include four identical types of HPV. In a study of about 3,200 women between 27 and 45 years, the mean follow-up time was 3.5 years, gardasil was 88% effective in preventing persistent infection, genital warts, and pre-existing lesions. Vaginal and vaginal cancer, cervical cancer damage and cervical cancer are related to the types of HPV. FDA's approval of Gardasil 9 in women between 27 and 45 years old is based on these results and new data on long-term follow-up from this study.

Gardasil is 88% effective in preventing persistent infection, genital warts .

The efficacy of gardas 9 in men between 27 and 45 years is derived from the data described above in women aged 27 to 45 years, as well as effective data from Gardasil in young men (from 16 to 26 years old) and immune data from a clinical trial in which 150 men, between 27 and 45 years of age, received 3-dose gardasil regimens for 6 months. The safety of gardasil 9 is evaluated in a total of 13,000 men and women. The most common side effects are soreness, swelling, redness and headache .

Almost all cases of cervical cancer are caused by HPV through sexual contact. There are more than 100 types of HPV, but most are harmless. In fact, most people get HPV at some point in their lives. Some types of HPV may not cause any symptoms, some can cause genital warts and some can lead to cervical cancer. Two strains of HPV (HPV 16 and HPV 18) account for 70% of all cervical cancers. These two types of HPV do not cause any symptoms, so you cannot know if you are infected with the virus. One of the ways to prevent cervical cancer is to get the HPV vaccine, sex relationship. safe sex and gynecological examination every 6 months.